Pharma Focus Asia

Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment

Friday, December 09, 2022

Chugai Pharmaceutical Co., Ltd. and Towa Pharmaceutical Co., Ltd. announced that Towa launched Edirol® Tablets 0.5 µg/0.75 µg (generic name: eldecalcitol, hereafter, Edirol Tablet) for an osteoporosis treatment (an active vitamin D3 preparation) upon the listing of the national health insurance (NHI) reimbursement price list today. Edirol Tablet was approved by the Ministry of Health, Labour and Welfare (MHLW) on August 15, 2022.

While Chugai takes responsibilities as a marketing authorization holder, Towa is solely responsible for marketing and providing information on appropriate use of Edirol Tablet. Chugai manufactures Edirol Tablet and supplies to Towa. Chugai continues to market and provide information on Edirol® Capsule 0.5 µg/0.75 µg (hereafter, Edirol Capsule). Towa markets an authorized generic (AG) version of Edirol Capsule.

Edirol is an active vitamin D3 derivative created by Chugai, which can improve calcium and bone metabolism. In Japan, Edirol was launched in April 2011 for the treatment of osteoporosis. In Prevention of Osteoporosis and Clinical Practice Guidelines 2015, Edirol is ranked as grade A as an active vitamin D3 preparation in the efficacy assessment to validate the increase in bone mineral density and decrease in vertebral fracture.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024